S troke is among the leading causes of mortality and disability worldwide. 1 Patients with ST-segment-elevation myocardial infarction (STEMI) are at increased risk of cerebrovascular events compared with the general population. 2 Common mechanisms of cerebrovascular events in patients with STEMI include cerebral embolism, plaque rupture with thrombosis in situ, and intracranial hemorrhage. Emboli of cardiac origin because of rhythm disturbances (mostly atrial fibrillation), mural thrombus, and severely impaired left ventricular ejection fraction (LVEF) are well-recognized sources of ischemic stroke. 3-6 Acute cerebrovascular and coronary thrombosis may coexist because of a systemic prothrombotic and inflammatory state accompanying plaque rupture. 7 Finally, potent fibrinolytic, antithrombotic, and antiplatelet agents and their combination used for the treatment of STEMI raise the risk of hemorrhagic stroke.
overall decline in the rate of cerebrovascular events, although the incidence of hemorrhagic stroke increased. 9, 10 Mechanical reperfusion using primary percutaneous coronary intervention (PCI) compared with fibrinolytic therapy further enhanced survival in patients with STEMI along with a significant reduction in the rates of hemorrhagic and total stroke. 11 Contemporary data on the incidence and implications of cerebrovascular complications in patients with STEMI managed with primary PCI are scarce. 12 This is especially true with regard to the long-term risk of cerebrovascular events. The large-scale, prospective, randomized, multicenter Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial with 3-year follow-up provides an opportunity to examine stroke rates after contemporary pharmacological treatment in patients with STEMI managed with primary PCI and to determine the types and predictors of stroke in this setting.
Methods
The HORIZONS-AMI trial has been previously described. [13] [14] [15] Briefly, 3602 patients ≥18 years of age with ≥1 mm ST-segment-elevation in ≥2 contiguous leads, new left bundle branch block, or true posterior infarction and symptoms consistent with AMI lasting >20 minutes but <12 hours undergoing primary PCI were randomized 1:1 to treatment with bivalirudin monotherapy versus unfractionated heparin plus a platelet glycoprotein IIb/IIIa receptor inhibitor (either abciximab or eptifibatide). Stroke or transient ischemic attack (TIA) within the previous 6 months or any permanent neurological deficit was exclusion criteria. Immediate coronary angiography with left ventriculography was performed after randomization, followed by triage to PCI, coronary artery bypass grafting (CABG), or medical management at the discretion of the physician. Eligible patients were randomly assigned again, in a 3:1 ratio, to either TAXUS Express 2 paclitaxel-eluting stents or otherwise similar Express 2 bare metal stents. HORIZONS-AMI was approved by the institutional review board or ethics committee at each participating center, and all enrolled patients provided informed written consent.
End Points
Two primary 30-day end points were prespecified: major bleeding not related to CABG and net adverse clinical events (including major bleeding or a composite of major adverse cardiovascular events, consisting of death, reinfarction, ischemia-driven target vessel revascularization, or stroke). 13 Disabling stroke was defined as an acute neurological event lasting >24 hours and resulting in disability or death, and TIA was defined as a temporary focal brain or retinal deficit caused by vascular disease that cleared completely in <24 hours. Cerebrovascular events that occurred during or within 30 days after the index hospitalization or later were considered early or late, respectively. Baseline anemia was defined as a hematocrit <39% for men and <36% for women. 16 Renal insufficiency was defined as a creatinine clearance of <60 mL/min estimated by the Cockcroft-Gault equation. 17 All events (including stroke) were adjudicated by an independent Clinical Events Committee blinded to treatment assignment. Clinical follow-up for all patients was performed at 1, 6, 12, 24, and 36 months.
Statistical Methods
Outcomes were stratified according to the presence or absence of cerebrovascular events (stroke or TIA). Categorical variables were compared with χ 2 statistics or Fisher exact test. Continuous variables are presented as medians with interquartile ranges and were compared using the Kruskal-Wallis test. Time to cerebrovascular event rates were estimated by the cumulative incidence function, accounting for the competing risk of all-cause death. Time-to-event curves were compared with the log-rank test. Multivariable analysis of the predictors of cerebrovascular events at follow-up was performed using Cox proportional hazards regression with stepwise selection using entry and exit criteria of P<0.1. The candidate variables entered into the model included age, sex, body mass index, creatinine clearance <60 mL/min anemia, diabetes mellitus, history of peripheral arterial disease, history of or new-onset atrial fibrillation, insertion of intra-aortic balloon pump (IABP), principal management strategy (primary PCI, CABG or medical management), and randomization to bivalirudin. Final models account for the competing risk of death by using the subdistribution regression methods by Fine and Gray. 18 To investigate the relationship between cerebrovascular events and subsequent mortality, each event was entered into a time-dependent Cox model adjusted for other previously identified baseline predictors of mortality. All analyses were 2-sided, and significance was established at the 0.05 level. All analyses were performed with SAS v 9.2 (SAS Institute, Cary, NC).
Results

Incidence and Correlates of Cerebrovascular Events
Of 3602 patients enrolled in HORIZONS-AMI, 72 (2.0%) experienced a cerebrovascular event during the 3-year followup period ( Figure 1A ), including 63 (1.7%) patients with stroke and 12 (0.3%) patients with a TIA. Three patients had both TIA and stroke. The timing and type of the cerebrovascular events are shown in Table 1 . A cerebrovascular event occurred in 29 of 72 patients (40.3%) within 30 days, including 20 patients who had stroke or TIA during the index hospitalization (27.8%). The incidence of cerebrovascular events steadily increased thereafter ( Figure 1B) , with 15 more patients (20.8%) having a cerebrovascular event between 30 days and 1 year, and 28 more patients (38.9%) experiencing a cerebrovascular event between 1 and 3 years. Of 63 patients with events, stroke was ischemic in origin in 58 (92.1%) and hemorrhagic in 5 (7.9%). More than half of all patients with stroke (33 patients; 52.3%) were disabling. By principal management strategy, a cerebrovascular event developed in 2.0%, 14.9%, and 1.9% of patients triaged to primary PCI, CABG, or medical therapy, respectively (P<0.0001; Figures 1C and  2 ). In the CABG cohort, all strokes occurred postoperatively, with 6 of 9 occurring within 30 days ( Figure 2 ).
WHAT IS KNOWN
• Patients with ST-segment-elevation myocardial infarction are at increased risk of cerebrovascular events compared with the general population.
WHAT THE STUDY ADDS
• In the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction trial, cerebrovascular events after ST-segment-elevation myocardial infarction in patients undergoing a primary percutaneous coronary intervention strategy:
• were uncommon in those treated with percutaneous coronary intervention or medically but frequent after coronary artery bypass grafting;
• often resulted in disability; • were associated with less frequent use of antiplatelet agents and with high rates of morbidity, bleeding events, and mortality. Baseline clinical characteristics, angiographic features, procedural data, and medication use in patients who developed a cerebrovascular event versus those who did not are presented in Tables 2 and 3 . Cerebrovascular events were associated with older age, diabetes mellitus, hypertension, congestive heart failure, peripheral arterial disease, prior CABG, lower LVEF, and lower baseline creatinine clearance and hemoglobin levels. Antithrombotic therapy and stent type were unrelated to the occurrence of cerebrovascular events. Thienopyridine use at discharge was slightly less common and diuretic and amiodarone use more common in patients with cerebrovascular events. Discharge use of statins, β-blockers, and angiotensin-converting enzyme inhibitors or receptor blocker was not associated with cerebrovascular events. The use of aspirin was significantly less in patients with cerebrovascular events both at 1 year and at 3 years.
Significantly more patients who developed a cerebrovascular event had a history of or new-onset atrial fibrillation (19.4% versus 6.4%; P=0.0002). Patients triaged to CABG had higher rates of atrial fibrillation compared with those triaged to primary PCI or medical management (35.9% versus 6.3% versus 4.2%, respectively; P<0.0001). The index hospitalization was significantly prolonged in patients with a cerebrovascular event (6 [4] [5] [6] [7] [8] [9] [10] [11] versus 5 [3] [4] [5] [6] [7] days; P=0.005).
Clinical Outcomes
As shown in Table 4 , occurrence of a cerebrovascular event was associated with the more frequent occurrence of other clinical end points, including mortality, reinfarction (mainly Q-wave myocardial infarction), ischemic target vessel revascularization, and major bleeding. Patients with a cerebrovascular event also had significantly higher rates of ischemia-driven revascularization in nontarget vessels (16.6% versus 9.6%; P=0.03).
Mortality at 3-year follow-up was 3-fold higher in patients who experienced a cerebrovascular event (20.5% versus 6.5%; P<0.0001; Figure 3 ). The risk was greater in patients with stroke compared with those with TIA (22.2% versus 0%; P=0.14) but was comparable with ischemic versus hemorrhagic stroke (22.4% versus 20.0%; P=0.94). Six of the 14 deaths (42.9%) among patients with stroke were adjudicated as directly related to the stroke itself.
Multivariable Analysis
Early cerebrovascular events (≤30 days) were independently predicted by creatinine clearance <60 mL/min (hazard In a time-updated covariate-adjusted multivariable analysis, occurrence of a cerebrovascular event was an independent predictor of 3-year mortality (HR, 2.39; 95% CI, 1.33-4.28; P=0.004; Figure 4 ).
Discussion
In this subanalysis from the large-scale HORIZONS-AMI trial in patients with STEMI managed with a primary PCI strategy using contemporary antithrombotic medications, cerebrovascular events (1) occurred in 2.0% of patients and were most frequent after CABG; (2) were often disabling; (3) steadily increased in incidence through 3-year follow-up; (4) powerfully correlated with older age, renal insufficiency, anemia, and diabetes mellitus; and (5) were strongly associated with substantial morbidity and mortality.
Early Cerebrovascular Events After STEMI
The 0.5% incidence of cerebrovascular events during the index hospitalization in patients with STEMI undergoing a primary PCI management strategy in the present analysis is similar to the 0.2% to 0.4% rate of cerebrovascular events after PCI in stable coronary artery disease and in those with non-STEMI using similar antithrombotic regimens in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 19, 20 The relatively low rate of stroke after primary PCI is consistent with reported studies showing a decline in the overall incidence of stroke in the mechanical reperfusion era. [9] [10] [11] 21 Primary PCI affords greater myocardial salvage and reduced infarct size, thus decreasing the odds of rhythm disturbances and mural thrombus formation, each of which have been linked to systemic embolism. 22 Compared with fibrinolytic therapy, primary PCI decreases rates of hemorrhagic stroke. 11 Only 1 patient in the present study experienced hemorrhagic stroke during the index hospitalization. Conversely, hemorrhagic stroke was more common (8 of 5372 patients [0.15%]) in the APEX-AMI trial, and all occurred within 48 hours of PCI. 12 The 1.3% incidence of stroke at 90-day follow-up in APEX-AMI is also somewhat greater than the rate we observed. These differences may be due, in part, to the higher risk profile of patients in APEX-AMI, which targeted enrollment of STEMI patients with larger myocardial infarction and did not exclude prior stroke. 23 In the present analysis, baseline renal insufficiency and triage to CABG independently predicted the occurrence of early cerebrovascular events. A link between renal insufficiency and cerebrovascular events has been described in the general population. In a meta-analysis of 33 prospective studies, a baseline-estimated glomerular filtration rate of <60 mL/min per 1.73 m 2 was associated with a 43% greater risk for stroke. 24 Although the mechanisms for this relationship are likely multifactorial, accelerated atherosclerosis in patients with chronic renal insufficiency is likely a major contributor.
Cerebrovascular Events in Patients Undergoing CABG
Cerebrovascular events are a known complication of CABG, with rates ranging from 1% to 5% in the elective setting. 25, 26 The pathophysiology of stroke after CABG is multifactorial, with stroke in this setting most commonly attributed to the development of cerebral emboli during aortic cross-clamping, low cardiac output resulting in cerebral hypoperfusion, and the occurrence of atrial fibrillation. The 14.9% incidence of cerebrovascular events in patients triaged to CABG in the present analysis is higher than that after elective CABG 25, 26 and after CABG for non-STEMI. 20, 27 This observation may be because of play of chance (small numbers) but may also be explained by greater hemodynamic instability and reduced left ventricular function in patients with STEMI. The higher incidence of stroke in patients who underwent in-hospital CABG compared with those treated with primary PCI or with medical management only in this analysis is also likely related to the higher risk profile of the CABG group, including a greater incidence of atrial fibrillation, older age, and higher Killip class (data not shown). Nonetheless, in both STEMI and non-STEMI, treatment with CABG during the index hospitalization was a powerful independent predictor for cerebrovascular events in the present and prior studies, with an HR ranging from 2.4 to 8.8. 20, 27 
Systemic Embolism Post-STEMI
Consistent with prior studies, a history of or new-onset atrial fibrillation and impaired LVEF correlated with the occurrence of early cerebrovascular events. Although the present study was not designed to determine the cause of stroke, the likely mechanism in each condition is systemic embolism. Atrial fibrillation has been strongly related to cerebrovascular events, especially in the elderly and in those with prior stroke, peripheral arterial disease, diabetes mellitus, and congestive heart failure. 28, 29 In the present study, all these characteristics were more frequent in patients developing a cerebrovascular event. LVEF recovery is dependent on the time to reperfusion, and patients with reduced LVEF are at enhanced risk of cerebrovascular events. 4, 5 In the Survival and Ventricular Enlargement (SAVE) trial, every 5% decline in LVEF was related to an 18% increased risk of stroke. 4 Thrombus formation in the left ventricle is more frequent in anterior infarcts, and its occurrence is related to the extent of myocardial dyskinesia. 3, 30 In a meta-analysis of 11 studies of anterior STEMI, mural thrombus diagnosed by echocardiography was associated with a >5-fold increase in the odds of embolism. 3 The efficacy of vitamin K antagonists in preventing thromboembolic stroke is well established. 31, 32 The use of vitamin K antagonists in addition to dual antiplatelet therapy after stent implantation is also well-known to increase bleeding and is thus frequently omitted or prematurely discontinued. 33 The rates of major and minor bleeding and blood transfusions were significantly increased in HORIZONS-AMI among patients who developed a cerebrovascular event, similar to that described in patients with non-STEMI. 20 A higher prevalence of risk factors, including older age, lower baseline hemoglobin level, and chronic renal insufficiency, likely contributed to the higher rates of bleeding in patients with stroke. 34 Bleeding, in turn, may contribute to more frequent discontinuation of antithrombin and antiplatelet medications in these patients, exposing them to higher rates of future cardiovascular and cerebrovascular events.
In a prior randomized trial and meta-analysis of 9 observational studies, IABP use was associated with an increased rate of cerebrovascular accident. 35, 36 In the present analysis, IABP use was twice as frequent in patients who developed a cerebrovascular event; however, after adjustment for various covariates, IABP was not independently predictive of cerebrovascular events. Similarly, in a recent randomized trial, there were no significant differences in rates of stroke between IABP and control groups. 37
Late Cerebrovascular Events After STEMI
In the present study, cerebrovascular events continued to occur after 30 days at a steady rate of 0.4% per year, reaching a cumulative incidence of 2% at 3-year follow-up. This is a lower rate than the 4.2% incidence of stroke at 3-year post-AMI in the randomized Valsartan in Acute Myocardial Infarction Trial (VALIANT) trial in high-risk patients with LVEF ≤35%. 38 The fact that diabetes mellitus and older age were the only significant predictors of stroke at late follow-up suggests advanced atherosclerosis in multiple vascular beds as a contributing factor. Because of their similar pathogenesis, coronary and cerebrovascular artery diseases frequently coexist. 8 The more severe the coronary atherosclerosis, the greater the likelihood of coexistent carotid disease. 39 In our study, the higher prevalence of peripheral arterial disease, coupled with a higher incidence of nontarget vessel coronary revascularization procedures in patients with cerebrovascular events, attests to the greater atherosclerotic burden in these patients.
Clinical Implications
Despite a relatively low incidence of cerebrovascular events after STEMI managed with a primary PCI strategy, the high rates of mortality, reinfarction, repeat ischemia, bleeding, and Hazard ratio (95% CI) P -value disability mandates physician attention to timely application of evidence-based diagnostic and therapeutic modalities to prevent these devastating complications. 40 Imaging techniques should be used appropriately to diagnose and treat mural thrombus, especially in patients with anterior infarcts. Prior history or newonset atrial fibrillation should prompt consideration for oral anticoagulation, and the decision to start vitamin K antagonists or novel antithrombin medications should be made after carefully weighing the risks of systemic embolism versus bleeding. In patients prescribed triple antithrombotic therapy, strict control of the international normalized ratio is essential, and an 81-to 100-mg daily dosage of aspirin should be used. 40, 41 Combination of warfarin and clopidogrel was shown to be safer than and as effective as triple therapy (warfarin, clopidogrel, and aspirin) in noncomplex patients treated with PCI using stents in a modest sized randomized trial, in which just 25% of the population had acute coronary syndrome. 42 Whether this holds in STEMI is unknown and cannot be assumed. Newer generation drug-eluting stents, with their improved safety profile in terms of minimizing the risk of stent thrombosis, allows for a shortening of the duration of triple antiplatelet therapy in patients at risk of systemic embolism and bleeding post-STEMI. 43 In both the HORIZONS-AMI and the APEX-AMI trials, the antiplatelet regimen included the combination of aspirin and clopidogrel. 12, 13 Newer generation thienopyridine and nonthienopyridine antiplatelet drugs, as well as novel oral antithrombotic agents, have improved ischemic outcomes in patients with acute coronary syndrome but do not reduce stroke. [44] [45] [46] More recently, the novel PAR-1 antagonist vorapaxar was found to reduce ischemic stroke when started 2 weeks to 12 months after myocardial infarction in patients without prior stroke or TIA, although at the risk of increased bleeding. 47 This agent may thus be of particular benefit in selected patients in normal sinus rhythm at otherwise high risk of stroke.
Risk factor modification and therapy with a statin, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, and appropriate antiplatelet agents may also reduce the risk of stroke in this patient population. [48] [49] [50] Given the common nature of coronary and cerebrovascular disease, screening for carotid atherosclerosis should also be routinely performed post-STEMI, especially in patients with diabetes mellitus.
Limitations
Although stroke events were prospectively collected, the present retrospective analysis was not prespecified in the original trial design and should therefore be considered hypothesisgenerating. Patients with stroke or TIA within the previous 6 months or any permanent neurological deficit were excluded. We were therefore unable to assess the impact of prior stroke on the occurrence of cerebrovascular events in the present analysis. Data regarding the late occurrence of atrial fibrillation and chronic use of oral anticoagulation were not available. Potent adenosine diphosphate antagonists, vorapaxar, and the novel oral anticoagulants were also not available during the time course of HORIZONS-AMI. Finally, although all neurological events were adjudicated by a clinical events committee using the original source documents (including neurological consultation and imaging studies), a neurologist was not mandated by the study.
Conclusions
In the HORIZONS-AMI trial, a cerebrovascular event within 3 years after STEMI in patients undergoing a primary PCI management strategy occurred in 2.0% of patients and was more frequent post-CABG. Stroke was often disabling and was strongly associated with high rates of death, reinfarction, recurrent ischemia, and major bleeding. Cerebrovascular events strongly correlated with atrial fibrillation, older age, renal insufficiency, anemia, and diabetes mellitus. Strategies to identify and treat the risk factors for cerebrovascular events post-STEMI should be implemented in a timely fashion to prevent these devastating complications.
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